Compare Merck & Co., Inc. (MRK) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nike Inc — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Nike Inc trades at $37.45 (market cap $56.52B). The key difference: Merck & Co., Inc. is far larger — about 6.5× Nike Inc's market cap, and Nike Inc pays the higher dividend (4.3%). Which is the better fit depends on your goals.
| MRK | NKE | |
|---|---|---|
Market Cap | $366.28B | $56.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $74.57 |
52-Week Low | $77.60 | $37.35 |
Enterprise Value | $413.04B | $58.53B |
Dividend Yield | 2.29% | 4.3% |
Volume | — | 8,887,180 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Nike (NKE) trades at $37.35, down 2.73% amid bearish technical signals and recent earnings volatility. The stock shows strong profitability metrics with 42.91% gross margins and 22.14% ROE, but faces revenue pressure with FY2025 sales declining to $46.31B. Analyst consensus remains positive with a $49.81 price target, though technical indicators signal caution with 17 sell signals versus 3 buy signals.
Nike's investment case balances strong brand equity and recent earnings beats against China market challenges and inventory pressures. The stock offers 33% upside to consensus targets but requires successful execution of the 'Win Now' turnaround strategy to overcome near-term headwinds in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
